Investment to accelerate Milacron’s growth and strengthen its position as a global leader in highly engineered plastic processing solutions. Milacron’s comprehensive suite of equipment ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

Independent company plans significant investment in innovation, both internal product development and external licensing and acquisitions, supported by Bain Capital investment Founded in 1678 ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

“Milacron is an iconic American manufacturing business with a 50-year legacy of driving innovation in plastics,” said Matt Evans, a partner at Bain Capital Special Situations in a statement.

Keith Largay joined Bain Capital’s real estate business as head of real estate capital markets, a spokesperson confirmed. It is a new position. Largay oversees the team’s debt and financing ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emerged triumphant on its quest to obtain Japanese drugmaker Mitsubishi Tanabe Pharma. Bain is laying out 510 ...

Batesville, Ind.-based Hillenbrand Inc. is selling the majority of its Milacron injection molding and extrusion business to an affiliate of Bain Capital for $287 million. The sale of 51 percent of ...

Boston-based Bain Capital hired a JLL senior leader as its head of real estate capital markets. Keith Largay has taken the role at the investment firm, Bain announced in a LinkedIn post.

TOKYO : Japan's Mitsubishi Chemical said on Friday it will sell pharmaceutical unit Tanabe Mitsubishi Pharma to U.S. private equity firm Bain Capital in a deal worth 510 billion yen ($3.36 billion ...

Private equity firm Bain Capital agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit, adding to a dealmaking boom in Japan. The deal values Mitsubishi Tanabe Pharma at about 510 billion ...